- 1.
Referansegruppen for Nasjonal kompetansetjeneste for bevegelsesforstyrrelser. Revidert terapianbefaling ved Parkinsons sykdom. https://helse-stavanger.no/seksjon/NKB/Documents/Nyhetsbulletin/Nyhetsbulletin%202014%20-%20nr.%202.pdf Lest 12.2.2023.
- 2.
Deutsche Gesellschaft für Neurologie. Idiopathisches Parkinson-Syndrom. Leitlinien für Diagnostik und Therapie in der Neurologie. Https://dnvp9c1uo2095.cloudfront.net/wp-content/uploads/2013/01/030010_LL_kurzfassung_ips_2016.pdf Lest 12.2.2023.
- 3.
Socialstyrelsen. Nationella riktlinjer för vård vid multipel skleros och Parkinsons sjukdom. Stöd för styrning och ledning. Stockholm: Socialstyrelsen, 2016.
- 4.
UK NICE Guideline. Parkinson's disease in adults. www.nice.org.uk/guidance/ng71 Lest 12.2.2023.
- 5.
Postuma RB, Berg D, Stern M et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30: 1591–601. [PubMed][CrossRef]
- 6.
Müller B, Larsen JP, Wentzel-Larsen T et al. Autonomic and sensory symptoms and signs in incident, untreated Parkinson's disease: frequent but mild. Mov Disord 2011; 26: 65–72. [PubMed][CrossRef]
- 7.
Tysnes OB, Vilming ST. Atypisk parkinsonisme. Tidsskr Nor Lægeforen 2008; 128: 2077–80. [PubMed]
- 8.
Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. Eur J Neurol 1999; 6: 539–47. [PubMed][CrossRef]
- 9.
Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498–508. [PubMed][CrossRef]
- 10.
Bjørnestad A, Forsaa EB, Pedersen KF et al. Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism Relat Disord 2016; 22: 48–53. [PubMed][CrossRef]
- 11.
Rascol O, Brooks DJ, Korczyn AD et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342: 1484–91. [PubMed][CrossRef]
- 12.
Dietrichs E, Odin P. Algorithms for the treatment of motor problems in Parkinson's disease. Acta Neurol Scand 2017; 136: 378–85. [PubMed][CrossRef]
- 13.
Erga AH, Alves G, Larsen JP et al. Impulsive and Compulsive Behaviors in Parkinson's Disease: The Norwegian ParkWest Study. J Parkinsons Dis 2017; 7: 183–91. [PubMed][CrossRef]
- 14.
Giladi N, Gurevich T, Djaldetti R et al. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord 2021; 91: 139–45. [PubMed][CrossRef]
- 15.
Bjerknes S, Toft M, Brandt R et al. Subthalamic nucleus stimulation in Parkinson's disease: 5-year extension study of a randomized trial. Mov Disord Clin Pract (Hoboken) 2021; 9: 48–59. [PubMed][CrossRef]
- 16.
Kvernmo N, Konglund AE, Reich MM et al. Deep brain stimulation for arm tremor. Ann Neurol 2022; 91: 585–601. [PubMed][CrossRef]
- 17.
Moosa S, Martínez-Fernández R, Elias WJ et al. The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease. Mov Disord 2019; 34: 1243–51. [PubMed][CrossRef]
()
Elektrokonvulsiv terapi (ECT) ved Parkinsons sykdom
11.06.2023Dietrichs og medarbeidere nevner ikke ECT som alternativ under avansert behandling av motoriske symptomer ved Parkinsons sykdom (1). Jeg kan heller ikke se at ECT er nevnt i terapianbefalingene som de viser til. I 2015 skrev Kellner og Kellner at New England…